New hope for hard-to-treat ovarian cancer: targeted drug combo shows promise
NCT ID NCT07285941
First seen Jan 10, 2026 · Last updated May 28, 2026 · Updated 23 times
Summary
This study tests a new drug combination (distamab vedotin plus carboplatin) in 20 people with advanced HER2-positive ovarian cancer who have not had chemotherapy before. The goal is to see if this combo can control the disease longer and with fewer side effects than standard treatment. Participants must have had surgery to remove most of the tumor and have HER2 protein levels of 2+ or 3+.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhe Jiang Cancer Hospital
RECRUITINGZhejiang, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.